세계의 아시트레틴 시장 : 제품 유형별, 용량별, 용도별, 유통 채널별, 최종 용도별 - 예측(2024-2032년)

Global Acitretin Market will indicate over 4.6% CAGR between 2024 and 2032, backed by booming pharmaceutical and healthcare infrastructure. According to Invest India reports, the pharmaceutical industry of India will hit USD 65 billion by 2024 and double to USD 130 billion by 2030. It supplies 60% of global vaccine production, meeting 70% of WHOs DPT and BCG vaccine demand, and 90% of measles vaccine demand. Acitretins adoption in clinical practice is catapulted by its proven clinical effectiveness and established safety profile in managing severe psoriasis.

Healthcare providers prefer treatments that offer reliable outcomes with minimal adverse effects, making acitretin a preferred choice. Its efficacy in controlling psoriasis symptoms like scaling, inflammation, and plaque formation enhances patient satisfaction and compliance. Moreover, the drugs safety profile supports long-term use, further bolstering its appeal among clinicians.

The overall acitretin industry is sorted based on product type, dosage strength, application, distribution channel, end-use, and region.

The generics segment will imply a notable CAGR during the forecast period. Generic versions of Acitretin offer cost-effective alternatives to branded medications, making treatment more accessible to a broader patient population. Additionally, as patents expire and generic alternatives become available, healthcare systems and insurers often prioritize cost-efficient options, catapulting demand. Moreover, the established efficacy and safety profile of acitretin encourages its adoption among healthcare providers seeking reliable treatments for psoriasis and related conditions.

The ichthyosis segment will procure a noticeable market share by 2032, because of the proven efficacy of acitretin in managing this rare genetic skin disorder characterized by dry, scaly skin. The medications ability to address the underlying causes of ichthyosis, coupled with its relative rarity, positions acitretin as a valuable therapeutic option, driving its demand specifically within this specialized segment of dermatological care.

North America acitretin market will hold a significant revenue share by 2032, attribute to the prevalence of psoriasis and related skin disorders, prompting a robust demand for effective treatments. Advancements in healthcare infrastructure and a strong emphasis on dermatological R&D contribute to increased awareness and accessibility of treatments. Moreover, patient advocacy groups and healthcare providers efforts to promote effective management strategies for chronic skin conditions usher the adoption of acitretin in North America, reflecting its growing importance in dermatological care.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
  • 3.2.2 Rising prevalence of psoriasis
  • 3.2.3 Advancements in treatment
  • 3.2.4 Growing awareness and diagnosis
  • 3.2.5 Industry pitfalls & challenges
  • 3.2.6 Stringent regulatory requirements
  • 3.2.7 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Branded
• 5.3 Generics

Chapter 6 Market Estimates and Forecast, By Dosage Strength, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2. 10mg
• 6.3. 25mg
• 6.4. 50mg

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Psoriasis
• 7.3 Ichthyosis
• 7.4 Darier disease
• 7.5 Pityriasis rubra pilaris
• 7.6 Solid organ transplants
• 7.7 Grover's disease
• 7.8 Lichen planus
• 7.9 Lupus erythematosus

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Amneal Pharmaceuticals, Inc.
• 10.2 Biophore.
• 10.3 Chongqing Huapont Pharmaceutical Co., Ltd.
• 10.4 Globe International Limited
• 10.5 GSK Plc
• 10.6 Merck KGaA
• 10.7 Prasco Laboratories
• 10.8 SGPharma Pvt Ltd
• 10.9 Sionc Pharmaceuticals Pvt. Ltd.
• 10.10 Sun Pharma Industries Limited